Glucagon-like peptide-1 receptor agonists and risk of substance use disorders among US veterans with type 2 diabetes: cohort study - PubMed
8 hours ago
- #GLP-1 receptor agonists
- #Type 2 diabetes
- #Substance use disorders
- Study investigates the association between GLP-1 receptor agonists and reduced risks of substance use disorders (SUDs) in US veterans with type 2 diabetes.
- Two protocols were used: Protocol 1 for individuals with no history of SUDs and Protocol 2 for those with pre-existing SUDs.
- Results show GLP-1 receptor agonists are associated with reduced risks of various SUDs, including alcohol, cannabis, cocaine, nicotine, and opioid use disorders.
- In individuals with pre-existing SUDs, GLP-1 receptor agonists were linked to fewer emergency department visits, hospital admissions, and lower mortality related to SUDs.
- The study suggests GLP-1 receptor agonists may have a preventive and therapeutic role in managing SUDs, warranting further research.